New Advances Continue to Improve Outcomes in Hodgkin Lymphoma
At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Catherine Diefenbach, MD, Perlmutter Cancer Center, New York, New York, discusses key updates in Hodgkin lymphoma, as presented at ASH 2025.
Dr Diefenbach highlights results from the S1826 trial comparing nivolumab plus AVD versus ABVD and the German Hodgkin Study Group trial evaluating BrECADD versus BEACOPP and reviews a novel prognostic model (A-HIPI) to improve risk stratification and improve treatment.
Transcript:
Hi, I'm Dr Catherine Diefenbach and I'm speaking to you from the LL&M Winter Symposium here in Amelia Island, so nice to get to talk to you all.
I'm going to be speaking tomorrow about the developments in Hodgkin lymphoma from the ASH 2025 meeting. I'm going to speak about 3 things, 2 trials and 1 risk stratification tool called the A-HIPI. I'll talk about the S1826 trial that was an American intergroup trial comparing NAVD to ABVD and I'll talk about the German Hodge lymphoma study group trial that looked at BrECADD compared to BEACOPP.
In both of those trials, the outcomes for patients were excellent and I'll go into the weeds and talk about some of the differences between those 2 trials. I think the take home point is that we have lots of great options for our advanced stage Hodge lymphoma patients.
I then also talked about a new prognostic score in Hodgkin lymphoma that looks at a lot of clinical variables and creates a matrix that allows you to assign a risk score that's a little more sophisticated than the old Hodgkin lymphoma IPI. This also is going to allow us to personalize treatment in a more precise way.
These are some of the exciting developments in Hodgkin lymphoma that I will share with you at the LL&M meeting.
Source:
Diefenbach C. My evolving approach to Hodgkin lymphoma: Lessons from 2025 data. Presented at LL&M Winter Symposium; January 30-February 1, 2026. Amelia Island, FL.
